Should Eli Lilly slide on data for obesity pill despite Q2 beat?

JHVEPhoto/iStock Editorial via Getty Images

Eli Lilly (NYSE:LLY) shares reached a new 52-week low on Thursday as concerns over late-stage trial data for the company’s highly anticipated oral weight loss therapy, orforglipron, overshadowed its better-than-expected Q2 2025 financials.

Citing initial results, the Indiana-based pharmaceutical giant said